Aman M G, White A J, Vaithianathan C, Teehan C J
J Autism Dev Disord. 1986 Sep;16(3):263-73. doi: 10.1007/BF01531659.
This was a double-blind, placebo-controlled crossover trial of imipramine (3 mg/kg/day) in 10 profoundly retarded residents. Two groups were formulated: one with depressivelike (or affective) symptoms and one with acting-out behaviors. Measures of drug response included ratings of ward behavior using the Aberrant Behavior Checklist, interval samples of behavior in the living units, and observations of behavior in a playroom situation. Results indicated that the drug caused behavioral deterioration in the Irritability, Lethargy/social withdrawal, and Hyperactivity dimensions of the rating scale, irrespective of subgroup. In addition, gross motor activity was significantly increased on the wards due to imipramine, and it was found that the affective group became less active and the acting-out group more active during free play. Physical side effects were uncommon. These unexpected adverse behavioral effects were discussed with respect to dosage and diagnostic considerations.
这是一项针对10名重度智障居民的双盲、安慰剂对照的丙咪嗪（3毫克/千克/天）交叉试验。研究分为两组：一组有抑郁样（或情感性）症状，另一组有冲动行为。药物反应的测量指标包括使用异常行为检查表对病房行为进行评分、生活单元中行为的间隔抽样以及在游戏室情境中对行为的观察。结果表明，无论亚组如何，该药物都会导致评定量表中易怒、嗜睡/社交退缩和多动维度的行为恶化。此外，由于丙咪嗪，病房中的总体运动活动显著增加，并且发现在自由玩耍期间，情感组变得不那么活跃，而冲动行为组变得更加活跃。身体副作用并不常见。针对剂量和诊断考虑因素对这些意外的不良行为影响进行了讨论。
